Jessi Zhang

Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji City, China
Author    Correspondence author
Journal of Vaccine Research, 2020, Vol. 10, No. 2   
Received: 26 Apr., 2020    Accepted: 06 May, 2020    Published: 14 Nov., 2003

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A scientific research team led by the Chinese scientist academician Chen Wei, announced that the team adopted the technical route of adenovirus vector to develop a recombinant novel coronavirus (2019-COV) vaccine, which has been approved to start clinical trials. As of April 2, 108 subjects in the phase I clinical trial of the novel coronavirus vaccine in Wuhan have completed vaccination。500 volunteers were recruited in the phase II clinical trial, the low and medium dose vaccines were selected for the trial. The purpose of the phase II clinical trial is to adjust and improve the procedures of clinical vaccination and to obtain statistical data on adverse reactions.

Vaccination; Adenovirus vector Vaccine; COVID-19; Phase I / II Clinical Trials

(The advance publishing of the abstract of this manuscript does not mean final published, the end result whether or not published will depend on the comments of peer reviewers and decision of our editorial board.)